Medicinal Chemistry

Welcome

Admissions

Curriculum

Seminar Program

Research

Faculty

Staff & PostDocs

Students

Alumni & Friends

Medicinal Chemistry HOME


Alumni and Friends

Debbie Heyl-Clegg Debbie Heyl-Clegg
Professor of Chemistry
Chemistry Department
Eastern Michigan University, Ypsilanti, Michigan
E-mail: Debbie.Heyl-Clegg@emich.edu


Education
Postdoctoral Research Fellow, Parke-Davis Pharmaceutical Research Division, Warner Lambert Company (1991-1992)
Ph.D. in Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan (1991)
(Ph.D. studies supported in part by the Pharmacological Sciences Training Program (NIH-GM07767))
M.S. in Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan (1987)
A.B. Summa cum laude in Chemistry, Lafayette College, Easton, Pennsylvania (1986)


Teaching
I have always felt a personal dedication to teaching, which has been my primary focus since joining the chemistry department faculty at Eastern Michigan University. I generally am responsible for upper level courses in biochemistry, introductory and intermediate level courses in organic chemistry, and occasionally, both general/introductory chemistry and graduate level advanced special topics courses. Teaching loads generally are heavy, 12 contact hours per semester distributed between upper and lower-level lecture courses and laboratories. We have 22 faculty in our closely-knit and supportive department with various specializations; I am the only medicinal chemist but often masquerade as a biochemist.


Research
The EMU chemistry department considers scholarly research an important component of faculty activity as well as an integral part of student education and training. Our thesis-based M.S. program provides a steady level of research activity in the labs, and facilitates the assimilation of undergraduates into research projects. The research in my group has mainly involved developing structure-activity relationships for deltorphins I and II (Tyr-D-Ala-Phe-Asp/Glu-Val-Val-Gly-NH2), opioid peptides isolated from amphibian skin. Deltorphins exhibit extremely high selectivity for the delta opioid receptor over the mu receptor. Like other opioids, the deltorphin family of peptides contains the amino acid residues which are known to interact directly with opioid receptors (Tyr and Phe) in the N-terminal "message" domain, but vary in the C-terminal "address" domain which gives rise to the varying selectivity. We have investigated this series of peptides over the past few years, primarily by modification of the amino acids to vary physicochemical parameters. In this way, the role of each receptor type may be probed, with the ultimate goal being the development of an opiate peptide with analgesic properties, yet devoid of the addictive side effects currently associated with opiate treatment. Recently, we have been able to summarize and quantitate the effects of several parameters on enhancement of opioid binding affinity (specifically, volume, area, diameter, shape, partition coefficient/lipophilicity, H-bonding capacity and polarizability of the side chains at certain residues) based on our binding data.

Our latest efforts have also been directed toward a new project, the development of peptide inhibitors for the enzyme alpha-amylase, which catalyzes the cleavage of glucose units from dietary starch as one means of controlling blood glucose levels. Inhibition of this glycosidase might be beneficial in reducing blood sugar peaks between meals in conjunction with insulin treatments in diabetic patients. The crystal structure of the enzyme complex with a natural 74-amino acid protein inhibitor, Tendamistat, indicates that only four segments comprised of 15 amino acids of the inhibitor actually interact directly at the active site. Smaller peptide analogs of this inhibitor which include these four key segments linked by novel amino acid spacers are being designed (with information from molecular modeling), synthesized, and purified and then analyzed for amylase inhibitory activity in a spectrophotometric assay. The length of the spacers can be varied to allow for variability in peptide backbone flexibility, and segments can be linked in different orders to mimic tertiary structure. Some analogs will be conformationally constrained to attempt to induce the proper molecular arrangement for binding to the enzyme. The conformation of active compounds will be studied by 2-D NMR. The aim is to develop smaller novel compounds, lacking the characteristic immunogenicity and lability of larger proteins, which can be better employed as peptidomimetic models.


Selected Publications

  1. Peptide inhibitors of a-amylase based on Tendamistat: Synthesis and kinetic studies; Deborah Heyl, Leo Solomon Lucas, Rebecca Himm, Jennifer Kappler, Jason Groom, Jeffrey Asbill, Jon Nzoma, Janice Lima and Mary Gillipsie (2001) In Proceedings of the Seventeenth American Peptide Symposium, in press.

  2. The role of backbone conformation in deltorphin II binding: A QSAR study of new analogs modified in the 5, 6 positions of the address domain: Stephen E. Schullery, David W. Rodgers, Sakambari Tripathy, Don Eranda Jayamaha, Medha D. Sanvordekar, Kutralanathan Renganathan, Carol Mousigian, and Deborah L. Heyl (2001) Bioorganic & Medicinal Chemistry 9/10, 2633-2642.

  3. Syntheis of a new group of deltorphin I/II analogs modified in the address domain with g-amino acids, and a QSAR study of their d/m opioid binding: Deborah L. Heyl, Medha D. Sanvordekar, Guzin Dogruyol, Mohamed D. Salamoun, David W. Rodgers, Kutralanathan Renganathan, Carol Mousigian and Stephen E. Schullery (1999) Protein and Peptide Letters, 6 (6), 359-366.

  4. Binding to d and m opioid receptors by deltorphin I/II analogues modified at the Phe3 and Asp4/Glu4 side chains: A report of 32 new analogues and a QSAR study: Stephen E. Schullery, Tasneem Mohammedshah, Hafida Makhlouf, Eleanor L. Marks, Benjamin S. Wilenkin, Sharleen Escobar, Carol Mousigian, and Deborah L. Heyl (1997) Bioorganic & Medicinal Chemistry, 5(12), 2221-2234.

  5. Developments in the structure-activity relationships for the d-selective opioid peptides of amphibian skin: D. L. Heyl and S. E. Schullery (1997) Current Medicinal Chemistry, 4, 117-150.

  6. Structural requirements for binding to the d opioid receptor: Alkyl replacements at the third residue of deltorphin I: Deborah L. Heyl, Hassiba Bouzit, and Carol Mousigian (1996) Letters in Peptide Science, 2, 277-284.

  7. Opioid receptor binding requirements for the d-selective peptide deltorphin I: Phe3 replacement with ring-substituted and heterocyclic amino acids: Deborah L. Heyl, Meena Dandabathula, Kathleen R. Kurtz and Carol Mousigian (1995) Journal of Medicinal Chemistry, 38, 1242-1246.

  8. Substitution of aromatic and nonaromatic amino acids for the Phe3 residue in the d-selective opioid peptide deltorphin I: Effects on binding affinity and selectivity: Deborah L. Heyl, Sharon J. Schmitter, Hassiba Bouzit, Thomas W. Johnson, Angela M. Hepp, Kathleen R. Kurtz, and Carol Mousigian (1994) International Journal of Peptide and Protein Research, 44, 420-426.


Personal
On the home front, I am married to a software engineering manager, Tom, and I am the devoted mother of two young boys: Danny, born in 1993, and Brad, born in 1998. I feel very fortunate for the flexibility in my professional career, which affords me the opportunity to spend a reasonable amount of time with my children as they grow up. During the spring/summer period from May-August, I elect not to teach, which at a teaching-oriented institution allows me to cut the time I spend at work to 2 days a week, for research only. The other days are free to spend on family activities, allowing me to feel balanced and fulfilled.



Questions/Comments
Rackham School of Graduate Studies | College of Pharmacy
page last modified: Wednesday, 12-Sep-2001 15:39:49 EDT
©2001 University of Michigan